Author

K. Zandi

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Bioengineering· 1 Immunology· 1 Microbiology· 1 Pathology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Research Focus:drug response / drug discovery· 3 Organism:human· 3 Research Focus:host-pathogen & immune response· 2 Research Focus:cell type annotation· 1 Research Focus:clustering· 1 Research Focus:differential expression· 1 Assay:flow cytometry· 1

Frequent Co-Authors

R. F. Schinazi· 4 shared S. Tao· 2 shared A. A. Upadhyay· 1 shared A. K. Boddapati· 1 shared A. Kosters· 1 shared A. Piantadosi· 1 shared B. LA SCOLA· 1 shared B. S. Dobosh· 1 shared

Activity by Year

2020-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 25 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersBioengineering

R. F. Schinazi

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Development of robust antiviral assays using relevant apical-out human airway organoids

J.-H. Lee, J. C. LeCher, E. Parigoris, N. Shinagawa, J. Sentosa, C. Manfredi, S. L. Goh, R. De, S. Tao, K. Zandi, F. Amblard, E. J. Sorscher, J. R. Spence, R. Tirouvanziam, R. F. Schinazi, S. Takayama

This paper develops AORBs, a high-throughput human airway organoid system, to robustly assess antiviral efficacy against SARS-CoV-2 with high throughput and clinical relevance.

bioRxiv · Jan 2, 2024 · PreprintBioengineering

Inactivation of SARS Coronavirus 2 and COVID-19 patient samples for contemporary immunology and metabolomics studies

D. J. Eddins, L. C. Bassit, J. Chandler, N. S. Haddad, K. Musall, J. Yang, A. Kosters, B. S. Dobosh, M. R. Hernandez, R. P. Ramonell, R. M. Tirouvanziam, F. E.-H. Lee, K. Zandi, R. F. Schinazi, E. Ghosn

This paper demonstrates optimal viral inactivation methods for SARS-CoV-2 and COVID-19 patient samples to enable safe handling at lower biosafety levels while preserving downstream assay fidelity.

bioRxiv · Oct 22, 2021Microbiology

GNS561 exhibits potent in vitro antiviral activity against SARS-CoV-2 through autophagy inhibition

P. Halfon, E. Bestion, K. Zandi, J. Andreani, J.-P. Baudoin, B. LA SCOLA, J.-L. Mege, S. Mezouar, R. F. Schinazi

This study shows GNS561, an autophagy inhibitor, has strong antiviral effects against SARS-CoV-2, both alone and in combination with remdesivir.

bioRxiv · Oct 6, 2020Pathology

Baricitinib treatment resolves lower airway inflammation and neutrophil recruitment in SARS-CoV-2-infected rhesus macaques

T. N. Hoang, M. Pino, A. K. Boddapati, E. G. Viox, C. E. Starke, A. A. Upadhyay, S. Gumber, K. Busman-Sahay, Z. Strongin, J. L. Harper, G. K. Tharp, K. L. Pellegrini, S. Kirejczyk, K. Zandi, S. Tao, , Bosinger

This study shows baricitinib reduces lung inflammation and neutrophil recruitment in SARS-CoV-2-infected rhesus macaques without affecting viral shedding or immune responses.

bioRxiv · Sep 16, 2020Immunology